{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:55:39Z","timestamp":1793163339849,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1053\/j.semnuclmed.2024.02.007","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T04:02:38Z","timestamp":1712203358000},"page":"581-590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prostate Cancer Theranostics With 177Lu-PSMA"],"prefix":"10.1053","volume":"54","author":[{"given":"Hojjat","family":"Ahmadzadehfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-7701","authenticated-orcid":false,"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0001","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0002","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00259-014-2978-1","article-title":"[(1) (7) (7)Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer","volume":"42","author":"Kratochwil","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0003","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13550-015-0114-2","article-title":"Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: A two-centre study","volume":"5","author":"Ahmadzadehfar","year":"2015","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.semnuclmed.2019.07.003","article-title":"PSMA-based theranostics: A step-by-step practical approach to diagnosis and therapy for mCRPC patients","volume":"50","author":"Ahmadzadehfar","year":"2020","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0007","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","article-title":"Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [ (177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0008","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1007\/s00259-021-05383-3","article-title":"The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [ (177)Lu]Lu-PSMA-617: A WARMTH multicentre study","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0010","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","article-title":"PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The Bad Berka experience since 2013","volume":"57","author":"Kulkarni","year":"2016","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2024.02.007_bib0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bju.14876","article-title":"TheraP: A randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (clinical trial protocol ANZUP 1603)","volume":"124","author":"Hofman","year":"2019","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0012","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2967\/jnumed.118.216820","article-title":"Clinical outcomes of (177)Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy","volume":"60","author":"Barber","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0013","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [ (177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): Secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0014","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2012.09.008","article-title":"A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer","volume":"63","author":"Parker","year":"2013","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0015","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S1470-2045(18)30216-X","article-title":"EMA guidance on radium-223 dichloride in prostate cancer","volume":"19","author":"Gourd","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0016","doi-asserted-by":"crossref","first-page":"55567","DOI":"10.18632\/oncotarget.15698","article-title":"Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0017","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2967\/jnumed.122.264456","article-title":"Safety and survival outcomes of (177)Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer with prior (223)Ra treatment: The RALU study","volume":"64","author":"Rahbar","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0018","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2967\/jnumed.123.266125","article-title":"(177)Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer and prior (223)Ra (RALU Study)","volume":"64","author":"Rahbar","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0019","unstructured":"FDA Approves Olaparib for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. 2020 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer."},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0020","unstructured":"FDA Approves Olaparib With Abiraterone and Prednisone (or Prednisolone) for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. 2023 https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration."},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0021","unstructured":"PSMAfore phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration resistant prostate cancer. ESMO: 2023 https:\/\/www.urotoday.com\/conference-highlights\/esmo-2023\/esmo-2023-prostate-cancer\/147587-esmo-2023-psmafore-phase-3-trial-of-177lu-lu-psma-617-in-taxane-naive-patients-with-mcrpc.html."},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0022","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ( (177)Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0023","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/RLU.0000000000001195","article-title":"Positive influence of 177Lu PSMA-617 therapy on bone marrow depression caused by metastatic prostate cancer","volume":"41","author":"Schlenkhoff","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0024","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0025","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0026","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving (177)Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0027","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0028","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2967\/jnumed.121.263638","article-title":"Why we did what we did: PSMA PET\/CT selection criteria for the VISION trial","volume":"63","author":"Kuo","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0029","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2967\/jnumed.119.233429","article-title":"Additional local therapy for liver metastases in patients with metastatic castration-resistant prostate cancer receiving systemic PSMA-targeted therapy","volume":"61","author":"Seifert","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0030","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.2967\/jnumed.122.265242","article-title":"PSMA PET Tumor-to-salivary gland ratio to predict response to [(177)Lu]PSMA radioligand therapy: An international multicenter retrospective study","volume":"64","author":"Hotta","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0031","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2967\/jnumed.122.264741","article-title":"Is (18)F-FDG PET needed to assess (177)Lu-PSMA therapy eligibility? A VISION-like, single-center analysis","volume":"64","author":"Seifert","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0032","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0033","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): A biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0034","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0035","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","article-title":"qPSMA: Semiautomatic software for whole-body tumor burden assessment in prostate cancer using (68)Ga-PSMA11 PET\/CT","volume":"60","author":"Gafita","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0036","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","article-title":"Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer","volume":"61","author":"Seifert","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0037","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0038","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[ (177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0039","first-page":"1","article-title":"Direct comparison of (99m)Tc-PSMA SPECT\/CT and (68)Ga-PSMA PET\/CT in patients with prostate cancer","volume":"8","author":"Albalooshi","year":"2020","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0040","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/pros.23379","article-title":"Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT\/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET\/CT","volume":"77","author":"Lawal","year":"2017","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0041","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.3390\/cancers15245824","article-title":"Diagnostic performance of (99m)Tc-iPSMA SPECT\/CT in the initial staging of patients with unfavorable intermediate-, high-, and very high-risk prostate cancer: A comparative analysis with (18)F-PSMA-1007 PET\/CT","volume":"15","author":"Vargas-Ahumada","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0042","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2967\/jnumed.122.264296","article-title":"Eligibility for (177)Lu-PSMA therapy depends on the choice of companion diagnostic tracer: A comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in metastatic castration-resistant prostate cancer","volume":"64","author":"Cook","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0043","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190380","article-title":"Therapeutic efficacy, prognostic variables and clinical outcome of (177)Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: Prognostic implications of high FDG uptake on dual tracer PET-CT vis-a-vis Gleason score in such cohort","volume":"92","author":"Suman","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0044","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1590\/0100-3984.2020.0044","article-title":"(68)Ga-PSMA PET\/CT: Effect of external cooling on salivary gland uptake","volume":"54","author":"Junqueira","year":"2021","journal-title":"Radiol Bras"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0045","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2967\/jnumed.119.226449","article-title":"Effect of external cooling on (177)Lu-PSMA uptake by the parotid glands","volume":"60","author":"Yilmaz","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0046","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-018-0408-2","article-title":"Impact of external cooling with icepacks on (68)Ga-PSMA uptake in salivary glands","volume":"8","author":"van Kalmthout","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0047","doi-asserted-by":"crossref","first-page":"55094","DOI":"10.18632\/oncotarget.19049","article-title":"Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer","volume":"8","author":"Gaertner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0048","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0049","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: The PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0050","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): An international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0051","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.7150\/thno.60222","article-title":"Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy","volume":"11","author":"Seifert","year":"2021","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0052","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0053","first-page":"S1281","article-title":"Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)","volume":"34 (suppl 2)","author":"Sartor","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0054","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2967\/jnumed.123.266952","article-title":"The imperative for comparative studies in nuclear medicine: Elevating (177)Lu-PSMA-617 in the treatment paradigm for mCRPC","volume":"65","author":"Rahbar","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.euf.2020.09.021","article-title":"Clinical trial protocol for LuTectomy: A single-arm study of the dosimetry, safety, and potential benefit of (177)Lu-PSMA-617 prior to prostatectomy","volume":"7","author":"Dhiantravan","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0056","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bju.15384","article-title":"UpFrontPSMA: A randomized phase 2 study of sequential (177) Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)","volume":"128","author":"Dhiantravan","year":"2021","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2024.02.007_bib0057","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of (177)Lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T10:01:19Z","timestamp":1722679279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299824000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0001299824000242"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.02.007","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer Theranostics With 177Lu-PSMA","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}